BsAbs Emerge as Dual Threat For Heme and Solid Tumors

By Marcus A. BanksBispecific antibodies (BsAbs) initially showed promise as an immunotherapy option against hematologic cancers but are now becoming valuable treatments for solid tumors as well, experts said at the 2025 ASCO Annual Meeting, in Chicago. The speakers highlighted the BsAb tarlatamab-dlle (Imdelltra, Amgen), which received FDA approval in 2024 for treating small cell lung cancer (SCLC) that has progressed on or after chemotherapy.BsAbs target multiple antigens to prime the immune sy